SIREN : 850259581
MTC PHARMA is a French company founded 6 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PARIS (75018), this company of category PME shows in 2021 a revenue of 3.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-25
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2021 |
|---|---|---|
| Revenue | N/C | 3 381 219 € |
| Net income | 115 257 € | 270 447 € |
| EBITDA | N/C | 310 265 € |
| Net margin | N/C | 8.0% |
In 2023, MTC PHARMA generates positive net income of 115 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2021-2023: 270 k€ -> 115 k€.
115 257 €
The debt ratio (= Financial debt / Equity x 100) stands at 21%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 48%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
20.692%
48.378%
72.5%
In 2023, the debt ratio of MTC PHARMA (20.69) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2023, the financial autonomy of MTC PHARMA (48.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2021, the repayment capacity of MTC PHARMA (0.06) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 36.11. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
36.112
In 2023, the liquidity ratio of MTC PHARMA (36.11) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2021, the interest coverage of MTC PHARMA (1.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Based on 220 transactions of similar company sales in 2023, the value of MTC PHARMA is estimated at 1 359 972 € (range 827 064€ - 1 911 815€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MTC PHARMA with other companies in the same sector:
The revenue of MTC PHARMA in 2021 is 3.4 M€.
Yes, MTC PHARMA generated a net profit of 115 k€ in 2023.
The headquarters of MTC PHARMA is located in PARIS (75018), in the department Paris.
The tax return of MTC PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MTC PHARMA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.